Pershing Edward - 22 Nov 2024 Form 4 Insider Report for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)

Reporting relationship: CEO, Director
Issuer ticker: PVCT
Reported as of: 22 Nov 2024
Net transaction value: +$230,005
SEC form: 4
Accepted by SEC: 25 Nov 2024, 17:12:09 UTC
Prior SEC filing: 17 Oct 2024
Next SEC filing: 02 Dec 2024
Source filing: View source filing
Reporting owner signature: /s/ Edward Pershing

Key filing fact

Pershing Edward filed Form 4 for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) on 25 Nov 2024.

Key facts

This page summarizes Pershing Edward's Form 4 filing for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 25 Nov 2024, 17:12.

Change

Previous filing in this sequence was filed on 17 Oct 2024.
Current net transaction value: +$230,005.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PVCT transaction Derivative

Series D-1 Convertible Preferred Stock

Purchase

Transaction value: $230,005
Shares: +80,365
Change %: +5%
Price: $2.86^*
Shares after: 1,691,704
Date: 22 Nov 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 803,650
Exercise price
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The Reporting Person acquired 80,365 shares of Series D-1 Preferred Stock in a private transaction for $230,000.

Footnote F2

Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").

Footnote F3

The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.